about
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell deathThe ZNF304-integrin axis protects against anoikis in cancerMetabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancerRole of Increased n-acetylaspartate Levels in Cancer.Targeting SRC in mucinous ovarian carcinoma.Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikisMetronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancerFocal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasisCalcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.Functional roles of Src and Fgr in ovarian carcinoma.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.Paraneoplastic thrombocytosis in ovarian cancer.Targeting c-MYC in Platinum-Resistant Ovarian CancerNeuroendocrine influences on cancer progression.Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.Src activation by β-adrenoreceptors is a key switch for tumour metastasis.Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.ATP11B mediates platinum resistance in ovarian cancer.FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.Neuroendocrine modulation of cancer progression.Estrous cycle modulates ovarian carcinoma growth.Surgical stress promotes tumor growth in ovarian carcinoma.SSRI use and clinical outcomes in epithelial ovarian cancer.Therapeutic Targeting of ATP7B in Ovarian Carcinoma.Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.Monocyte subpopulations in angiogenesis.Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.Why stress is BAD for cancer patientsPrevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto RicoCurcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway
P50
Q24632721-1B9DC5D9-0DCC-4F6F-BBFB-F5BF4ECA4AE1Q28115264-B4A41B7D-4375-426A-BB62-10DA6FEA45C8Q28609305-DD65754B-3ECC-4886-A956-433ED1B2E91BQ30488862-CC93FA25-7661-4897-AB31-301D390E153AQ33638051-869CAEAD-6C41-4172-A5E1-9D011602CB5DQ33815723-4ADF6B06-F6EB-4B8D-BA18-33E3D073749EQ33875597-39D78058-B991-4A76-B6F9-B13382E100A5Q33911213-9C1E47B6-6AB8-4021-A9B8-B609693B5823Q33956803-1A714FF3-CFA0-4EFE-8316-FA88C492F7AAQ34285076-082BC2B9-804A-426E-8747-49717888C1FBQ34290146-CF5D2B67-FE33-4EAA-A8CB-3F4F99A5BE13Q34433163-A650BC5B-FA82-4C7B-B438-424C1D9DAE26Q34458449-4F01BF21-A696-4256-A05B-C9EF526C93AAQ34796603-C8BB29A9-BB04-44DC-871D-D3D542529200Q35205410-BA1C5D82-6BB9-4ABE-81FA-9F654B366791Q35551991-E6BCC56F-39A9-4239-92BA-362E054ED153Q35691011-58CB6C37-56E6-499B-A97C-362501823008Q35812402-C732CEF3-DD66-4BFD-9159-3F93079A4B9BQ36132771-3149289E-6815-43C0-AB3F-689A4F98B045Q36306358-E6B3B761-2952-463A-8084-38B4FBCB27D0Q36359684-6226856C-00D4-49EE-B737-4EE608166756Q36405508-3C60C3DC-1F4A-40B4-8A12-F0821E936894Q36568221-BC60FC6B-FAAE-49FA-A4D7-9C507E3B290DQ36579843-7009A2E2-B5CB-4A3B-BCDC-A62B83167AD4Q36759360-3D503ACE-078B-4399-8B8D-380BC11EA172Q36768803-AC7E9231-3741-4B4D-8EB3-EFEEAEDDD375Q36793431-1A6ADF82-D221-4FF1-BFD8-A82F2FD7EBD3Q36867341-174B8001-EE7B-4CDC-AB76-6A7FADD78450Q37062821-B8F4924B-31B4-4DF7-86B4-38C643B6808CQ37071784-6CEABE63-DE5D-4F8F-9010-D8236C7CB8EBQ37345175-3C22F9C3-1B27-4642-AF29-0180BF7097FAQ37353385-0F70D737-4D36-41B7-8961-97F1967A5BB1Q37362871-0241DC3B-B475-4E6D-ADF5-0D72C8840614Q37365130-6E918656-8A16-4FF1-BDAD-4E1A618D71D1Q37398815-1B75E609-C85A-4FBF-AB44-1F7EECBC191EQ38189962-D5719E60-B13F-475F-9EE1-3C548FD4D449Q40252227-00046AA1-2366-4453-B3D8-97DCBC5CBBA8Q42127137-C753E371-DCE6-4F79-BC60-0039ACE0B0B0Q59806524-8DEB9232-AA14-4970-8F88-8F82DDBFD596Q80421999-B978CD31-9C70-498D-A58F-CE77766534FC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Guillermo Armaiz-Pena
@ast
Guillermo Armaiz-Pena
@en
Guillermo Armaiz-Pena
@es
Guillermo Armaiz-Pena
@nl
Guillermo Armaiz-Pena
@sl
type
label
Guillermo Armaiz-Pena
@ast
Guillermo Armaiz-Pena
@en
Guillermo Armaiz-Pena
@es
Guillermo Armaiz-Pena
@nl
Guillermo Armaiz-Pena
@sl
altLabel
Guillermo Armaiz Pena
@en
Guillermo Armaiz
@en
Guillermo Armaiz-Pena
@en
prefLabel
Guillermo Armaiz-Pena
@ast
Guillermo Armaiz-Pena
@en
Guillermo Armaiz-Pena
@es
Guillermo Armaiz-Pena
@nl
Guillermo Armaiz-Pena
@sl
P108
P106
P108
P1153
14057523000
P21
P31
P496
0000-0002-9081-5339